{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:00:14Z","timestamp":1781100014710,"version":"3.54.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lfs.2026.124454","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:44:59Z","timestamp":1778600699000},"page":"124454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent advances in the molecular interactions of anti-cancer peptides with cellular targets"],"prefix":"10.1016","volume":"400","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-3492","authenticated-orcid":false,"given":"Davood","family":"Zaeifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124454_bb0005","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2026.124454_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2026.124454_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/02648725.2022.2082157","article-title":"Anti-cancer peptides: their current trends in the development of peptide-based therapy and anti-tumor drugs","volume":"39","author":"Lath","year":"2023","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.lfs.2026.124454_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.900418","article-title":"Mesenchymal stem cell-derived antimicrobial peptides as potential anti-neoplastic agents: new insight into anticancer mechanisms of stem cells and exosomes","volume":"10","author":"Moeinabadi-Bidgoli","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2026.124454_bb0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2026.124454_bb0030","article-title":"The current landscape of the antimicrobial peptide melittin and its therapeutic potential","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124454_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/cells11244016","article-title":"Recent advances of studies on cell-penetrating peptides based on molecular dynamics simulations","volume":"11","author":"Ouyang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2026.124454_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/s22114005","article-title":"To assist oncologists: an efficient machine learning-based approach for anti-cancer peptides classification","volume":"22","author":"Alsanea","year":"2022","journal-title":"Sensors (Basel)"},{"key":"10.1016\/j.lfs.2026.124454_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.822","article-title":"The role of cell-penetrating peptides in potential anti-cancer therapy","volume":"12","author":"Zhou","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.lfs.2026.124454_bb0050","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1021\/acsami.2c20388","article-title":"Cancer-responsive multifunctional nanoplatform based on peptide self-assembly for highly efficient combined cancer therapy by alleviating hypoxia and improving the immunosuppressive microenvironment","volume":"15","author":"Wu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.lfs.2026.124454_bb0055","article-title":"Modified CLEC3A-derived antimicrobial peptides lead to enhanced antimicrobial activity against drug-resistant bacteria","volume":"12","author":"Meinberger","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.lfs.2026.124454_bb0060","article-title":"Molecular dynamics simulation of antimicrobial peptide CM15 in staphylococcus aureus and Escherichia coli model bilayer lipid","volume":"21","author":"Zaeifi","year":"2023","journal-title":"Iran. J. Biotechnol."},{"key":"10.1016\/j.lfs.2026.124454_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112908","article-title":"Novel peptide therapeutic approaches for cancer treatment","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2026.124454_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101381","article-title":"Discovery, optimization, and clinical application of natural antimicrobial peptides","volume":"9","author":"Rodriguez","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.lfs.2026.124454_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.eururo.2005.12.043","article-title":"Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines","volume":"50","author":"Lehmann","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.lfs.2026.124454_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189776","article-title":"Is it possible to create antimicrobial peptides based on the amyloidogenic sequence of ribosomal S1 protein of P. aeruginosa?","volume":"22","author":"Grishin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124454_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10050945","article-title":"PNC-27, a chimeric p53-Penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis","volume":"10","author":"Sarafraz-Yazdi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.lfs.2026.124454_bb0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.biomaterials.2010.08.080","article-title":"Post-formulation peptide drug loading of nanostructures for metered control of NF-kappaB signaling","volume":"32","author":"Pan","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2026.124454_bb0095","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1158\/1078-0432.CCR-10-3310","article-title":"NEMO-binding domain peptide inhibits constitutive NF-kappaB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma","volume":"17","author":"Gaurnier-Hausser","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124454_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095404","article-title":"A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma","volume":"9","author":"Habineza Ndikuyeze","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2026.124454_bb0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136176","article-title":"Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis","volume":"6","author":"Aftabizadeh","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.lfs.2026.124454_bb0110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.chembiol.2017.06.013","article-title":"Cell permeable stapled peptide inhibitor of Wnt signaling that targets beta-catenin protein-protein interactions","volume":"24","author":"Dietrich","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.lfs.2026.124454_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117021","article-title":"Development of a penetratin-conjugated stapled peptide that inhibits Wnt\/beta-catenin signaling","volume":"73","author":"Tsuchiya","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.lfs.2026.124454_bb0120","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-25-B031","article-title":"Abstract B031: a phase 1\/2 trial of FOG-001, a first-in-class direct \u03b2-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)","volume":"24","author":"Klempner","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2026.124454_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117961","article-title":"Peptide inhibitors: breaking cancer code","volume":"297","author":"Coburn","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2026.124454_bb0130","article-title":"Rational design of peptide-based inhibitors disrupting protein-protein interactions","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.lfs.2026.124454_bb0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40820-020-00452-y","article-title":"Human iPS cells loaded with MnO(2)-based nanoprobes for photodynamic and simultaneous enhanced immunotherapy against cancer","volume":"12","author":"Liu","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.lfs.2026.124454_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734956","article-title":"A systematic review of the tumor-infiltrating CD8(+) T-cells\/PD-L1 Axis in high-grade glial tumors: toward personalized Immuno-oncology","volume":"12","author":"Shadbad","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124454_bb0145","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-20-3435","article-title":"Safety, antitumor activity, and T-cell responses in a dose-ranging phase I trial of the oncolytic peptide LTX-315 in patients with solid tumors","volume":"27","author":"Spicer","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124454_bb0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00262-024-03679-5","article-title":"TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1\/M2 macrophage polarization shift and CD8(+) T cell priming","volume":"73","author":"Lee","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2026.124454_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102623","article-title":"Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines","volume":"36","author":"Zhou","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.lfs.2026.124454_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41420-024-01932-5","article-title":"Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth","volume":"10","author":"Furukawa","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.lfs.2026.124454_bb0165","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1039\/D5BM00284B","article-title":"An injectable oncolytic hydrogel platform for in situ dendritic cell vaccination to boost antitumor immunity","volume":"13","author":"Wang","year":"2025","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.lfs.2026.124454_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123402","article-title":"GSH-activable and cytolytic iPep-coupled immune nanoagonist for cancer synergetic therapy","volume":"322","author":"Ji","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2026.124454_bb0175","article-title":"Hollow CoFe nanozymes integrated with oncolytic peptides designed via machine-learning for tumor therapy","volume":"20","author":"Li","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.lfs.2026.124454_bb0180","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3892\/ijo.2020.5099","article-title":"Anticancer peptide: physicochemical property, functional aspect and trend in clinical application (review)","volume":"57","author":"Chiangjong","year":"2020","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lfs.2026.124454_bb0185","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/RPS.RPS_75_24","article-title":"Exploring the potential of anticancer peptides as therapeutic agents for cancer treatment","volume":"20","author":"Ghavimi","year":"2025","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.lfs.2026.124454_bb0190","article-title":"Investigation of anticancer peptides derived from Arca species using in silico analysis","volume":"30","author":"Wu","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2026.124454_bb0195","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1021\/acs.bioconjchem.5c00123","article-title":"Modulation of membrane-disruptive activity of Melittin via N- and C-terminal PEGylation strategies","volume":"36","author":"Chen","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.lfs.2026.124454_bb0200","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/cb1001558","article-title":"Describing the mechanism of antimicrobial peptide action with the interfacial activity model","volume":"5","author":"Wimley","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.lfs.2026.124454_bb0205","doi-asserted-by":"crossref","first-page":"11685","DOI":"10.1038\/s41467-025-66748-y","article-title":"A scalable reinforcement learning approach for screening large peptide libraries for bioactive peptide discovery","volume":"16","author":"Pandey","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124454_bb0210","doi-asserted-by":"crossref","first-page":"E2811","DOI":"10.1073\/pnas.1715350115","article-title":"Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors","volume":"115","author":"Wyatt","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2026.124454_bb0215","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1021\/acs.biochem.8b00156","article-title":"Nuclear magnetic resonance-based structural characterization and backbone dynamics of recombinant bee venom Melittin","volume":"57","author":"Ramirez","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.lfs.2026.124454_bb0220","doi-asserted-by":"crossref","first-page":"12124","DOI":"10.1021\/bi700978h","article-title":"Beta-sheet pore-forming peptides selected from a rational combinatorial library: mechanism of pore formation in lipid vesicles and activity in biological membranes","volume":"46","author":"Rausch","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.lfs.2026.124454_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214657","article-title":"Structural characterization of PPTI, a kunitz-type protein from the venom of Pseudocerastes persicus","volume":"14","author":"Banijamali","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2026.124454_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102399","article-title":"Mechanistic insight into the early stages of toroidal pore formation by the antimicrobial peptide Smp24","volume":"15","author":"Bertelsen","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2026.124454_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202306900","article-title":"Peptide Amphiphile-mediated assembly and fusion of anisotropic amorphous particles for enamel remineralization","volume":"34","author":"Tang","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.lfs.2026.124454_bb0240","article-title":"In silico discovery of anticancer peptides from Sanghuang","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124454_bb0245","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00216-020-03013-9","article-title":"Correlated fluorescence microscopy and multi-ion beam secondary ion mass spectrometry imaging reveals phosphatidylethanolamine increases in the membrane of cancer cells over-expressing the molecular chaperone subunit CCTdelta","volume":"413","author":"Fletcher","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.lfs.2026.124454_bb0250","article-title":"Cationic antimicrobial peptides: potential templates for anticancer agents","volume":"12","author":"Varela-Quitian","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.lfs.2026.124454_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216676","article-title":"Antimicrobial peptide LL-37 is bactericidal against Staphylococcus aureus biofilms","volume":"14","author":"Kang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2026.124454_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26073117","article-title":"The potential of peptide-based inhibitors in disrupting protein-protein interactions for targeted cancer therapy","volume":"26","author":"Afonso","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124454_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/ph13100300","article-title":"Characterization of iRGD-ligand modified arginine-histidine-rich peptides for nucleic acid therapeutics delivery to alphavbeta3 integrin-expressing cancer cells","volume":"13","author":"Egorova","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.lfs.2026.124454_bb0270","doi-asserted-by":"crossref","first-page":"230","DOI":"10.15698\/cst2020.10.232","article-title":"Endocytosis in the adaptation to cellular stress","volume":"4","author":"Lopez-Hernandez","year":"2020","journal-title":"Cell Stress"},{"key":"10.1016\/j.lfs.2026.124454_bb0275","article-title":"ALA-A2 is a novel anticancer peptide inspired by alpha-Lactalbumin: a discovery from a computational peptide library, in silico anticancer peptide screening and in vitro experimental validation","volume":"7","author":"Lerksuthirat","year":"2023","journal-title":"Global Chall."},{"key":"10.1016\/j.lfs.2026.124454_bb0280","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.23.01107","article-title":"Results from first-in-human phase I dose-escalation study of a novel bicycle toxin conjugate targeting EphA2 (BT5528) in patients with advanced solid tumors","volume":"42","author":"Bashir","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2026.124454_bb0285","doi-asserted-by":"crossref","first-page":"S511","DOI":"10.1016\/j.annonc.2024.08.713","article-title":"647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: a phase I\/II study","volume":"35","author":"Fontana","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2026.124454_bb0290","doi-asserted-by":"crossref","first-page":"S526","DOI":"10.1016\/j.annonc.2024.08.737","article-title":"671P LuMIERE: a phase I\/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors","volume":"35","author":"McConathy","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2026.124454_bb0295","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1021\/acs.biomac.5c00154","article-title":"Hybrid anticancer peptide synergistically improving cancer cell uptake and inducing apoptosis mediated by membrane fusion","volume":"26","author":"Jia","year":"2025","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.lfs.2026.124454_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115131","article-title":"Therapeutic peptides: recent advances in discovery, synthesis, and clinical translation","volume":"26","author":"Zheng","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124454_bb0305","doi-asserted-by":"crossref","first-page":"20137","DOI":"10.1021\/jacs.9b09563","article-title":"Fluorescence monitoring of peptide transport pathways into large and giant vesicles by supramolecular host-dye reporter pairs","volume":"141","author":"Barba-Bon","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.lfs.2026.124454_bb0310","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/anie.202011185","article-title":"An amphiphilic Sulfonatocalix[5]arene as an activator for membrane transport of lysine-rich peptides and proteins","volume":"60","author":"Pan","year":"2021","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.lfs.2026.124454_bb0315","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3389\/fphar.2020.01208","article-title":"Antimicrobial peptide reverses ABCB1-mediated chemotherapeutic drug resistance","volume":"11","author":"Luo","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124454_bb0320","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41597-024-03388-9","article-title":"DCTPep, the data of cancer therapy peptides","volume":"11","author":"Sun","year":"2024","journal-title":"Sci. Data"},{"key":"10.1016\/j.lfs.2026.124454_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9061249","article-title":"Comparison of a short linear antimicrobial peptide with its disulfide-cyclized and cyclotide-grafted variants against clinically relevant pathogens","volume":"9","author":"Koehbach","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.lfs.2026.124454_bb0330","first-page":"229","article-title":"Mitochondrial targeted peptide (KLAKLAK)(2), and its synergistic radiotherapy effects on apoptosis of radio resistant human monocytic leukemia cell line","volume":"11","author":"Bahmani","year":"2021","journal-title":"J. Biomed. Phys. Eng."},{"key":"10.1016\/j.lfs.2026.124454_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2022.107962","article-title":"Strategies employed in the design of antimicrobial peptides with enhanced proteolytic stability","volume":"59","author":"Lai","year":"2022","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.lfs.2026.124454_bb0340","doi-asserted-by":"crossref","first-page":"22974","DOI":"10.1021\/acsami.8b06125","article-title":"Nanoscale Melittin@Zeolitic imidazolate frameworks for enhanced anticancer activity and mechanism analysis","volume":"10","author":"Li","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.lfs.2026.124454_bb0345","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1016\/j.annonc.2022.07.604","article-title":"476P First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors","volume":"33","author":"Eskens","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2026.124454_bb0350","article-title":"Integrated design of a membrane-lytic peptide-based intravenous nanotherapeutic suppresses triple-negative breast cancer","volume":"9","author":"Chen","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.lfs.2026.124454_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge","volume":"8","author":"Nedeljkovic","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2026.124454_bb0360","doi-asserted-by":"crossref","first-page":"32448","DOI":"10.18632\/oncotarget.25963","article-title":"\u201cTwo hits - one stone\u201d; increased efficacy of cisplatin-based therapies by targeting PCNA\u2019s role in both DNA repair and cellular signaling","volume":"9","author":"Sogaard","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2026.124454_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01361","article-title":"A novel Cecropin-LL37 hybrid peptide protects mice against EHEC infection-mediated changes in gut microbiota, intestinal inflammation, and impairment of mucosal barrier functions","volume":"11","author":"Wei","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124454_bb0370","doi-asserted-by":"crossref","first-page":"12188","DOI":"10.1021\/acs.jmedchem.2c00862","article-title":"Structure-based design, optimization, and evaluation of potent stabilized peptide inhibitors disrupting MTDH and SND1 interaction","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2026.124454_bb0375","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.1021\/acsomega.2c06766","article-title":"One new acid-activated hybrid anticancer peptide by coupling with a desirable pH-sensitive anionic partner peptide","volume":"8","author":"Chang","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.lfs.2026.124454_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/imo2.70063","article-title":"Artificial intelligence-driven anticancer peptide discovery","volume":"2","author":"Wu","year":"2025","journal-title":"IMetaOmics"},{"key":"10.1016\/j.lfs.2026.124454_bb0385","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41467-024-45766-2","article-title":"Design of target specific peptide inhibitors using generative deep learning and molecular dynamics simulations","volume":"15","author":"Chen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124454_bb0390","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btad718","article-title":"DeepProSite: structure-aware protein binding site prediction using ESMFold and pretrained language model","volume":"39","author":"Fang","year":"2023","journal-title":"Bioinformatics"},{"key":"10.1016\/j.lfs.2026.124454_bb0395","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae348","article-title":"CELA-MFP: a contrast-enhanced and label-adaptive framework for multi-functional therapeutic peptides prediction","volume":"25","author":"Fang","year":"2024","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.lfs.2026.124454_bb0400","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac606","article-title":"AFP-MFL: accurate identification of antifungal peptides using multi-view feature learning","volume":"24","author":"Fang","year":"2023","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.lfs.2026.124454_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/biom13121735","article-title":"Advances in drug design and development for human therapeutics using artificial intelligence-II","volume":"13","author":"Wei","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.lfs.2026.124454_bb0410","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41467-025-67226-1","article-title":"Deep learning guided design of protease substrates","volume":"17","author":"Martin-Alonso","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124454_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138880","article-title":"Discovery of anticancer peptides from natural and generated sequences using deep learning","volume":"290","author":"Yue","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.lfs.2026.124454_bb0420","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3389\/fmicb.2019.01257","article-title":"Antimicrobial peptides: potential application in liver cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2026.124454_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/nano9040638","article-title":"Lipid-based nanoparticles: application and recent advances in cancer treatment","volume":"9","author":"Garcia-Pinel","year":"2019","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.lfs.2026.124454_bb0430","article-title":"A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124454_bb0435","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ygyno.2020.11.013","article-title":"A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer","volume":"160","author":"Chelariu-Raicu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.lfs.2026.124454_bb0440","doi-asserted-by":"crossref","first-page":"30599","DOI":"10.1038\/s41598-025-13110-3","article-title":"Computational and experimental discovery of peptide inhibitors targeting survivin for therapeutic potential in cancer","volume":"15","author":"Ahmadi","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2026.124454_bb0445","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1038\/s41467-019-10647-6","article-title":"Non-equilibrium dynamics of a nascent polypeptide during translation suppress its misfolding","volume":"10","author":"Alexander","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526002638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526002638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:15:38Z","timestamp":1781097338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526002638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":89,"alternative-id":["S0024320526002638"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124454","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the molecular interactions of anti-cancer peptides with cellular targets","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"124454"}}